| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Total revenue | $0-100.0% | $479K-93.6% | $7.5M+275.0% | $2.0M-87.5% | $16.0M | $0 |
| Cost of sales | $100.2M+22.8% | $81.6M+73.6% | $47.0M+280.1% | $12.4M+550.2% | $1.9M | — |
| Research and development | $186.2M+32.4% | $140.6M+37.1% | $102.6M-4.0% | $106.8M-18.7% | $131.4M+61.1% | $81.6M |
| Selling, general and administrative | $257.0M+27.1% | $202.2M+38.6% | $145.9M+63.8% | $89.1M+50.4% | $59.2M | — |
| Total operating expenses | $543.4M+28.0% | $424.5M+43.6% | $295.5M+41.9% | $208.3M+8.2% | $192.6M+84.6% | $104.3M |
| Loss from operations | -$22.1M+74.7% | -$87.6M+19.7% | -$109.2M+16.8% | -$131.2M+24.3% | -$173.4M-66.3% | -$104.3M |
| Interest income | $12.7M-7.7% | $13.8M+0.4% | $13.7M+256.1% | $3.9M+953.8% | $366K-76.5% | $1.6M |
| Interest expense | -$14.4M-0.5% | -$14.3M+5.3% | -$15.1M+5.5% | -$16.0M+9.2% | -$17.6M-5150.7% | -$335K |
| Loss from termination of revenue interest purchase agreement | $0 | $0+100.0% | -$49.1M | $0 | $0 | — |
| Other income (expense), net | $2.4M+95.5% | $1.2M+143.0% | -$2.8M-873.7% | $365K+162.7% | -$582K-203.1% | -$192K |
| Loss before provision for income taxes | -$21.4M+75.3% | -$86.9M+46.5% | -$162.4M-14.3% | -$142.1M-69.2% | -$84.0M+18.7% | -$103.3M |
| Provision for income taxes | $1.9M+88.0% | $1.0M+3.9% | $991K+115.5% | -$6.4M-17413.5% | $37K+516.7% | $6K |
| Net loss | -$23.4M+73.4% | -$87.9M+46.2% | -$163.4M-20.5% | -$135.7M-61.5% | -$84.0M+18.7% | -$103.3M |
| Net loss per share, basic (in dollars per share) | -$470.00+74.6% | -$1850.00+53.8% | -$4000.00+0.2% | -$4010.00-44.8% | -$2770.00 | — |
| Net loss per share, diluted (in dollars per share) | -$470.00+74.6% | -$1850.00+53.8% | -$4000.00+0.5% | -$4020.00-45.1% | -$2770.00 | — |
| Weighted-average shares of common stock outstanding, basic (in shares) | 50.20B+5.6% | 47.52B+16.2% | 40.89B+20.8% | 33.84B+11.6% | 30.32B | — |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 50.20B+5.6% | 47.52B+16.2% | 40.89B+20.3% | 33.98B+12.1% | 30.32B | — |
| Total product sales, net | ||||||
| License and other revenue | ||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.